Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer
Kristiaan Lenos1, Anna M. Grawenda2, Kristen Lodder3, Marieke L. Kuijjer4, Amina F.A.S. Teunisse3, Emmanouela Repapi2, Lukasz F. Grochola2, Frank Bartel5, Pancras C. W. Hogendoorn6, Peter Wuerl7, Helge Taubert8, Anne-Marie Cleton-Jansen4, Gareth L Bond2,*, and Aart G Jochemsen1